HOME >> BIOLOGY >> NEWS
A vaccine to kill tapeworm

A VACCINE for pigs could help save the 50,000 people a year in poor countries killed by a gruesome parasite. Initial trials suggest it is nearly 100 per cent effective.

The vaccine, developed by a team at the University of Melbourne, Australia, targets a tapeworm called Taenia solium. The adult form, caught from eating undercooked pork, grows only inside the human intestine, stealing nutrients from the host.

This can be debilitating. But far worse is what can happen if people swallow any of the microscopic eggs shed in vast numbers in the faeces of those carrying the adult form. The eggs hatch in the intestine and the immature parasites, known as oncospheres, burrow through the gut wall. They then migrate through the body and lodge themselves in muscles, the eyes and the brain, causing a disease called cysticercosis.

Its symptoms vary depending on the location and number of what are called cysticerci. Many people have no serious symptoms, but some go blind, become confused, suffer difficulty with balance or have epileptic seizures. Heavy infections can kill, often as a result of inflammation after the parasites die. The parasite has been virtually eliminated in developed countries, but even in the US there are around 1000 cases each year, mainly among immigrants. In central and South America, Asia and Africa, millions of people have symptoms of the disease.

While humans are the main host for T. solium, pigs are the intermediate host, and an essential step in the tapeworm's life cycle. If a pig eats the eggs then, as in humans, the eggs hatch in the intestine, burrow through the gut wall and travel to muscles, where they form cysticerci. The infection rarely causes symptoms in pigs.

Only cysticerci- not eggs- can develop into the adult form, so if you prevent infection in pigs, you can break the life cycle, says team member Charles Gauci. The Australian group has created a vaccine based on two proteins found on the oncosphere. The vacci
'"/>


13-Jul-2005


Page: 1 2

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
3. Handicapping tuberculosis may be the way to a better vaccine
4. Developing a more effective vaccine for tuberculosis
5. New target for HIV/AIDS drugs and vaccine discovered
6. Genomic analysis uncovers new targets for HIV vaccine
7. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
8. Universal flu vaccine being tested on humans
9. From clinical cancer research: rethinking therapeutic cancer vaccine trials
10. Paving the way toward a vaccine against Alzheimers disease
11. Mucosal-surface immune function discoveries could boost vaccine research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: vaccine kill tapeworm

(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... presented new data on the relationship of genetics and hypertension at the ... Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... will present at the Sidoti & Company Emerging Growth ... will be held at the New York Marriott Marquis. ... will be available through the investor relations section of ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: